Hereditary Cancer Risk, Diagnostics, and Treatment Strategies Practice Test

Reclassification is updating how we interpret a genetic variant as new information becomes available. It isn’t about changing the test method or making an initial call without evidence, and it isn’t driven by patient preference. Instead, as more data accumulate, the confidence in whether a variant is benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic can shift.

Several kinds of evidence push a reclassification. Population frequency data from large databases help judge if a variant is too common in healthy people to cause disease. Functional studies that show the variant alters gene or protein function provide direct evidence of impact. Segregation data from families reveal whether the variant tracks with the disease across relatives. Additional considerations include case-control studies, the presence of the variant in other affected individuals, de novo occurrence, and computational predictions, all integrated according to established guidelines.

For example, a rare variant found in a single patient with a strong phenotype may be labeled a variant of uncertain significance if evidence is limited. If later population data show the variant is present at a higher frequency in the general population than expected for a disease, it may be downgraded toward benign. Conversely, if multiple family members with the disease carry the variant and functional studies demonstrate a damaging effect, it can be upgraded toward pathogenic.

In short, reclassification reflects an evolving interpretation of pathogenicity as new, supporting information becomes available.